SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?


To: Bhag Karamchandani who wrote (4508)6/17/1998 12:55:00 PM
From: tommysdad  Read Replies (2) | Respond to of 6136
 
<<Can some one offer an empirical definition of " stabilized" ?>>

They didn't get worse.

I'm not being glib -- that's really what that means.

SF asks what this data means -- good or bad. Essentially, a PI trial is a safety trial and any efficacy on the order of what they are reporting is not statistically significant and translation to PII/III is fairly random. So, if you're a glass-half-full kind of guy, it's "good", if you're a glass-half-empty kind of guy, it's "neutral". All this data means is that they can go forward to PII, which we already knew they had done.

In a rational market, this news would have little impact.



To: Bhag Karamchandani who wrote (4508)6/17/1998 11:40:00 PM
From: Bhag Karamchandani  Read Replies (2) | Respond to of 6136
 
Re: AG3340; AGPH latest statement begs the question: What happened to the majority (close to 75 % 0f the patients (47 in total)) who were not included in the "stabilized" category?? Was period of treatment with AG3340 a factor??

Also are there any early indications of how AG3340 works with non- advanced ( again how does AGPH or anyone define advanced ) cancers?

Is the glass one-third full and two thirds empty or vice versa????

I found the press release quite ambiguous. Hope it was not deliberate. Is the reference to second generation MMP a way to play down expectations re AG 3340? Very much hope we do not have another Thymatiq unfolding. Why not simply publish the statistical data summary????